AffiliationDepartment of Endocrinology Manchester Royal Infirmary Manchester UK.
MetadataShow full item record
AbstractA 52-year-old lady was referred after a 5 cm left adrenal mass was detected on computed tomography (CT) scanning. She was asymptomatic although was noted to have acromegalic facies. Blood pressure (BP) was normal but plasma normetanephrines were raised to 2.81 mmol/l (<1.09) and urinary normetadrenaline excretion 5.3 μmol/24 h (0-4.3). Adrenal biochemistry screen was otherwise normal. Metaiodobenzylguanidine (MIBG) scan demonstrated uptake in the adrenal lesion. Growth hormone (GH) nadir on oral glucose tolerance test (OGTT) was 2.2 ng/ml with an elevated IGF1 level of 435 ng/ml (72-215), confirming acromegaly biochemically. The remainder of the pituitary screen was normal. A magnetic resonance imaging (MRI) scan of the pituitary revealed an enlarged pituitary gland with a microadenoma/cyst of 2-3 mm in diameter. Alpha blockade was achieved with a titrated dose of phenoxybenzamine before a successful laparoscopic hand-assisted left adrenalectomy. Postoperative biochemical testing revealed a normal plasma normetanephrine level of 0.6 nmol/l (<1.09) and a metanephrine level of 0.35 nmol/l (<0.46 nmol/l). Nadir on OGTT was normal at 0.07 ng/ml with an IGF1 level within the reference range at 111 ng/ml (75-215). Histology demonstrated a well-circumscribed and encapsulated oval mass with microscopic features typical for a phaeochromocytoma. The sections stained strongly positive for GHRH in 20% of cells on immunocytochemistry. Genetic analysis showed no pathogenic mutation. This is a report of the rare condition of a phaeochromocytoma co-secreting GHRH resulting in clinical and biochemical acromegaly. Neuroendocrine tumours can stain positive for GHRH without coexisting acromegaly, but the resolution of patient symptoms and normalisation of serum GH and IGF1 levels following surgery imply that this was functional secretion. Pituitary surgery should be avoided in such cases.
CitationPhaeochromocytoma and acromegaly: a unifying diagnosis. 2014, 2014:140036 Endocrinol Diabetes Metab Case Rep
JournalEndocrinology, Diabetes & Metabolism Case Reports
- GHRH secretion from a pancreatic neuroendocrine tumor causing gigantism in a patient with MEN1.
- Authors: Srirangam Nadhamuni V, Iacovazzo D, Evanson J, Sahdev A, Trouillas J, McAndrew L, R Kurzawinski T, Bryant D, Hussain K, Bhattacharya S, Korbonits M
- Issue date: 2021 Jun 1
- Diagnostic challenges and management of a patient with acromegaly due to ectopic growth hormone-releasing hormone secretion from a bronchial carcinoid tumour.
- Authors: Kyriakakis N, Trouillas J, Dang MN, Lynch J, Belchetz P, Korbonits M, Murray RD
- Issue date: 2017
- Ectopic secretion of growth hormone-releasing hormone (GHRH) in neuroendocrine tumors: relevant clinical aspects.
- Authors: Doga M, Bonadonna S, Burattin A, Giustina A
- Issue date: 2001
- Ectopic growth hormone-releasing hormone secretion by a bronchial carcinoid tumor: clinical experience following tumor resection and long-acting octreotide therapy.
- Authors: Butler PW, Cochran CS, Merino MJ, Nguyen DM, Schrump DS, Gorden P
- Issue date: 2012 Jun
- Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.
- Authors: Gola M, Doga M, Bonadonna S, Mazziotti G, Vescovi PP, Giustina A
- Issue date: 2006